Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
26 October 2022 | Story Leonie Bolleurs | Photo Supplied
Dr Carol Chi Ngang
Dr Carol Chi Ngang, a category C2-rated researcher and research fellow in the UFS Free State Centre for Human Rights, has been appointed as the UNDP Human Rights Research Chair at the National University of Lesotho, where he is currently affiliated.


A National Research Foundation category C2-rated researcher and research fellow in the Free State Centre for Human Rights at the University of the Free State (UFS), Dr Carol Chi Ngang, has been appointed as United Nations Development Programme (UNDP) Human Rights Research Chair at the National University of Lesotho, where he is currently affiliated. 

According to Dr Ngang, the Human Rights Chair was established with the broad mandate to undertake and promote cutting-edge policy research, curriculum development, and community engagement. He says the chair is envisaged to generate a steady stream of research outputs on various aspects of human rights in Lesotho, and most importantly, to explore the human rights components of the Sustainable Development Goals.

For establishing the Human Rights Chair and funding its programme activities, Dr Ngang expresses his gratitude to the United Nations Tripartite Partnership (UNTPP), the Office of the High Commissioner for Human Rights (OHCHR), and the United Nations Development Programme (UNDP) Lesotho.

Knowledge-based foundation for a human rights culture

Dr Ngang states that the establishment of the UNDP Human Rights Chair in the Faculty of Law at the National University of Lesotho is not only timely, but also indispensable in the sense that it provides the opportunity to lay a solid knowledge-based foundation for a human rights culture in Lesotho to respond to and seek to redress the exigencies and the lived experiences of the Basotho. 

“With the country’s political landscape characterised for the last decades by, among others, a distressed economy, shaky coalition governments, and instability, Lesotho’s human rights record is not an impressive one.”

Dr Ngang elaborates, “In spite of a cabinet decision taken as far back as 1995 and the adoption of the Sixth Amendment to the Constitution Act in 2011 – with explicit provision for the establishment of the Lesotho Human Rights Commission – 27 years down the line the august institution, which is supposed to oversee the promotion and protection of human rights in Lesotho, is yet to see the light of day. Lesotho remains one of the few countries in Africa and around the world that is yet to put in place a human rights commission to ensure protection of the vulnerable population, of which the constitutionally guaranteed fundamental rights are threatened on a daily basis.”

According to him, one of the most pressing issues in the human rights field currently, is the establishment of the Lesotho Human Rights Commission. “It is a central concern not only for our funders and the Ministry of Law and Justice and the many other active forces that have invested time and resources in the process, but importantly, also for the Lesotho society at large,” he states.

“Without the commission, the vulnerability of the population is multiplied.”

Effecting real transformation in the human rights situation in Lesotho

Dr Ngang says in the absence of a human rights commission, besides focusing on research and the dissemination of knowledge, the Human Rights Chair will additionally cover gaps in the areas of advocacy, amicus curiae interventions, and public interest litigation in human rights matters before the courts.

“It is our anticipation that the research outputs generated by the Human Rights Chair will be utilised productively, including by Lesotho-based civil society organisations, to inform policy advocacy and most essentially, leverage policy formulation, decision making, and resource allocation for the realisation of human rights in the country.”

Dr Ngang also foresees that it will shape the direction of governance and governmental actions in meeting the global Sustainable Development Goal targets, as well as the strategic objective of national transformation as outlined in the Lesotho National Strategic Development Plan II. 

The Human Rights Chair, he says, has established working relations with the Ministry of Law and Justice, as well as a collaborative partnership with the Lesotho NGO sector, and envisages doing so with the private sector and other major stakeholders. “These strategic alliances are intended to ensure that knowledge generated by the chair through research is utilised by the relevant stakeholders to effect real transformation as far as the human rights situation in Lesotho is concerned.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept